3,230,000 SHARES OF COMMON STOCK OF MONAKER GROUP, INC. UNDERWRITING AGREEMENT
Exhibit 1.1
3,230,000
SHARES OF COMMON STOCK OF
May 13,
2021
Kingswood Capital
Markets, division of Benchmark Investments, Inc.
00
Xxxxxxx
Xxxxx
Xxx
Xxxx, XX 00000
As the
Representative of the
Several
underwriters, if any, named in Schedule I hereto
Ladies
and Gentlemen:
The
undersigned, Monaker Group, Inc., a company incorporated under the
laws of Nevada (collectively with its subsidiaries and affiliates,
including, without limitation, all entities disclosed or described
in the Registration Statement as being subsidiaries or affiliates
of Monaker Group, Inc., the “Company”), hereby
confirms its agreement (this “Agreement”) with the
several underwriters (such underwriters, including the
Representative (as defined below), the “Underwriters” and each an
“Underwriter”) named in
Schedule I hereto
for which Kingswood Capital Markets, division of Benchmark
Investments, Inc. is acting as representative to the several
Underwriters (the “Representative” and if
there are no Underwriters other than the Representative, references
to multiple Underwriters shall be disregarded and the term
Representative as used herein shall have the same meaning as
Underwriter) on the terms and conditions set forth
herein.
It is
understood that the several Underwriters are to make a public
offering of the Public Shares as soon as the Representative deems
it advisable to do so. The Public Shares are to be initially
offered to the public at the public offering price set forth in the
Prospectus Supplement.
It is
further understood that you will act as the Representative for the
Underwriters in the offering and sale of the Closing Shares and, if
any, the Option Shares in accordance with this
Agreement.
ARTICLE
I.
DEFINITIONS
17.1 Definitions.
In addition to the terms defined elsewhere in this Agreement, for
all purposes of this Agreement, the following terms have the
meanings set forth in this Section 1.1:
“Action” shall have the
meaning ascribed to such term in Section 3.1(k).
“Affiliate” means with
respect to any Person, any other Person that, directly or
indirectly through
one or more intermediaries, controls or is controlled by or is
under common control with such Person as such terms are used in and
construed under Rule 405 under the Securities Act.
“Board of Directors” means
the board of directors of the Company.
“Business Day” means any
day other than Saturday, Sunday or other day on which commercial
banks in The City of New York are authorized or required by law to
remain closed; provided, however, for clarification, commercial
banks shall not be deemed to be authorized or required by law to
remain closed due to “stay at home”,
“shelter-in-place”, “non-essential
employee” or any other similar orders or restrictions or the
closure of any physical branch locations at the direction of any
governmental authority so long as the electronic funds transfer
systems (including for wire transfers) of commercial banks in The
City of New York are generally are open for use by customers on
such day.
“Closing” means the
closing of the purchase and sale of the Closing Shares pursuant to
Section 2.1.
“Closing Date” means the
hour and the date on the Trading Day on which all conditions
precedent to (i) the Underwriters’ obligations to pay the
Closing Purchase Price and (ii) the Company’s obligations to
deliver the Closing Shares, in each case, have been satisfied or
waived, but in no event later than 10:00 a.m. (New York City time)
on the second (2nd) Trading Day
following the date hereof or at such earlier time as shall be
agreed upon by the Representative and the Company.
“Closing Purchase Price”
shall have the meaning ascribed to such term in Section 2.1(b),
which aggregate purchase price shall be net of the underwriting
discounts and commissions.
“Closing Shares” shall
have the meaning ascribed to such term in Section
2.1(a).
“Commission” means the
United States Securities and Exchange Commission.
“Common Stock” means the
common stock of the Company, par value $0.00001per share, and any
other class of securities into which such securities may hereafter
be reclassified or changed.
2
“Common Stock Equivalents”
means any securities of the Company or the Subsidiaries which would
entitle the holder thereof to acquire at any time Common Stock,
including, without limitation, any debt, preferred stock, right,
option, warrant or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the
holder thereof to receive, Common Stock.
“Company Auditor” means
TPS Xxxxxx, with offices located at 0000 Xxxxxxx 0, Xxxxx 000,
Xxxxx Xxxx, XX 00000.
“Company Special Counsel”
means The XxXxxxx Law Firm, P.C.
“Disclosure Schedules”
means the Disclosure Schedules of the Company delivered
concurrently herewith.
“Effective Date” shall
have the meaning ascribed to such term in Section
3.1(f).
“EGS” means Ellenoff
Xxxxxxxx & Schole LLP, with offices located at 0000
Xxxxxx
xx xxx Xxxxxxxx, Xxx Xxxx, Xxx Xxxx 00000.
“Exchange Act” means the
Securities Exchange Act of 1934, as amended, and the rules and
regulations promulgated thereunder.
“Execution Date” shall
mean the date on which the parties execute and enter into this
Agreement.
“Exempt Issuance” means
the issuance of (a) shares of Common Stock or options to employees,
officers or directors of the Company pursuant to any stock or
option plan duly adopted for such purpose by a majority of the
non-employee members of the Board of Directors or a majority of the
members of a committee of non-employee directors established for
such purpose, (b) securities upon the exercise or exchange of or
conversion of any Public Shares issued hereunder and/or other
securities exercisable or exchangeable for or convertible into
shares of Common Stock issued and outstanding on the date of this
Agreement, provided that such securities have not been amended
since the date of this Agreement to increase the number of such
securities or to decrease the exercise price, exchange price or
conversion price of such securities or to extend the term of such
securities, (c) securities issued in connection with the
Company’s pending Share Exchange Agreement with HotPlay
Enterprise Limited (“HotPlay Agreement”) and
its stockholders;(d) securities issued pursuant to acquisitions or
strategic transactions approved by a majority of the disinterested
directors of the Company, provided that such securities are issued
as “restricted securities” (as defined in Rule 144) and
carry no registration rights that require or permit the filing of
any registration statement in connection therewith, and provided
that any such issuance shall only be to a Person (or to the equity
holders of a Person) which is, itself or through its subsidiaries,
an operating company or an owner of an asset in a business
synergistic with the business of the Company and shall provide to
the Company additional benefits in addition to the investment of
funds, but shall not include a transaction in which the Company is
issuing securities primarily for the purpose
3
of
raising capital or to an entity whose primary business is investing
in securities; (e ) up to $10 million of securities in a financing
transaction for which the securities are issued in restricted form
with no registration rights; and (f) means the issuance of shares
of restricted Common Stock to consultants and for conversion of
outstanding debts.
“FCPA” means the Foreign
Corrupt Practices Act of 1977, as amended.
“FINRA” means the
Financial Industry Regulatory Authority.
“GAAP” shall have the
meaning ascribed to such term in Section 3.1(i).
“Indebtedness” means (a)
any liabilities for borrowed money or amounts owed in excess of
$50,000 (other than trade accounts payable incurred in the ordinary
course of business), (b) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others,
whether or not the same are or should be reflected in the
Company’s consolidated balance sheet (or the notes thereto),
except guaranties by endorsement of negotiable instruments for
deposit or collection or similar transactions in the ordinary
course of business; and (c) the present value of any lease payments
in excess of $50,000 due under leases required to be capitalized in
accordance with GAAP.
“Liens” means a lien,
charge, pledge, security interest, encumbrance, right of first
refusal, preemptive right or other restriction.
“Lock-Up Agreements” means
the lock-up agreements that are delivered on the date hereof by
each of the Company’s officers and directors, in form and
substance reasonably satisfactory to the Representative and
EGS.
“Material Adverse Effect”
means (i) a material adverse effect on the legality, validity or
enforceability of any Transaction Document, (ii) a material adverse
effect on the results of operations, assets, business, prospects or
condition (financial or otherwise) of the Company and the
Subsidiaries, taken as a whole or (iii) a material adverse effect
on the Company’s ability to perform in any material respect
on a timely basis its obligations under any Transaction
Document.
“Offering” shall have the
meaning ascribed to such term in Section 2.1(c).
“Option Closing Date”
shall have the meaning ascribed to such term in Section
2.2(c).
“Option Closing Purchase
Price” shall have the meaning ascribed to such term
in Section 2.2(b),
which aggregate purchase price shall be net of the underwriting
discounts and commissions.
“Option Shares” shall have
the meaning ascribed to such term in Section 2.2(a).
“Over-Allotment Option”
shall have the meaning ascribed to such term in Section
2.2.
4
“Person” means an
individual or corporation, partnership, trust, incorporated or
unincorporated association, joint venture, limited liability
company, joint stock company, government (or an agency or
subdivision thereof) or other entity of any kind.
“Preliminary Prospectus”
means, if any, any preliminary prospectus relating to the Public
Shares included in the Registration Statement or filed with the
Commission pursuant to Rule 424(b).
“Proceeding” means an
action, claim, suit, investigation or proceeding (including,
without limitation, an informal investigation or partial
proceeding, such as a deposition), whether commenced or
threatened.
“Prospectus” means the
final prospectus filed for the Registration Statement.
“Prospectus Supplement”
means, if any, any supplement to the Prospectus complying with Rule
424(b) of the Securities Act that is filed with the
Commission.
“Public Shares” means,
collectively, the Closing Shares and, if any, the Option
Shares.
“Registration Statement”
means, collectively, the various parts of the registration
statement prepared
by the Company on Form S-3 (File No. 333-224309) with respect to
the Public Shares, each as amended as of the date hereof, including
the Prospectus and Prospectus Supplement, if any, the Preliminary
Prospectus, if any, and all exhibits filed with or incorporated by
reference into such registration statement.
“Required Approvals” shall
have the meaning ascribed to such term in Section
3.1(e).
“Rule 424” means Rule 424
promulgated by the Commission pursuant to the Securities Act, as
such Rule may be amended or interpreted from time to time, or any
similar rule or regulation hereafter adopted by the Commission
having substantially the same purpose and effect as such
Rule.
“SEC Reports” shall have
the meaning ascribed to such term in Section 3.1(i).
“Securities Act” means the
Securities Act of 1933, as amended, and the rules and
regulations
promulgated thereunder.
“Share Purchase Price”
shall have the meaning ascribed to such term in Section
2.1(b).
“Subsidiary” means any
subsidiary of the Company and shall, where applicable,
also
include any direct or indirect subsidiary of the Company formed or
acquired after the date hereof.
5
“Trading Day” means a day
on which the principal Trading Market is open for
trading.
“Trading Market” means any
of the following markets or exchanges on which the Common Stock is
listed or quoted for trading on the date in question: the NYSE
American, the Nasdaq Capital Market, the Nasdaq Global Market, the
Nasdaq Global Select Market, the New York Stock Exchange, OTCQX or
OTCQB (or any successors to any of the foregoing).
“Transaction Documents”
means this Agreement and all exhibits and schedules hereto, the
Lock-Up Agreements, and any other documents or agreements executed
in connection with the transactions contemplated
hereunder.
“Transfer Agent” means
Colonial Stock Transfer Co, Inc., with offices located at 00
Xxxxxxxx Xxxxx, Xxxxx 000, Xxxx Xxxx Xxxx, XX 00000, and any
successor transfer agent of the Company.
ARTICLE
II.
PURCHASE
AND SALE
2.1
Closing.
(a) Upon the terms and
subject to the conditions set forth herein, the Company agrees to
sell in the aggregate 3,230,000 shares of Common Stock and each
Underwriter agrees to purchase, severally and not jointly, at the
Closing, the number of shares of Common Stock (the
“Closing
Shares”) set forth opposite the name of such
Underwriter on Schedule
I hereof.
(b) The aggregate
purchase price for the Closing Shares shall equal the amount set
forth opposite the name of such Underwriter on Schedule I hereto (the
“Closing
Purchase
Price”). The purchase price for one Share shall be
$2.50 (the “Share
Purchase Price”).
(c) On the Closing
Date, each Underwriter shall deliver or cause to be delivered to
the Company, via wire transfer, immediately available funds equal
to such Underwriter’s Closing Purchase Price and the Company
shall deliver to, or as directed by, such Underwriter its
respective Closing Shares and the Company shall deliver the other
items required pursuant to Section 2.3 deliverable at the Closing.
Upon satisfaction of the covenants and conditions set forth in
Sections 2.3 and 2.4, the Closing shall occur at the offices of EGS
or such other location as the Company and Representative shall
mutually agree. The Public Shares are to be offered initially to
the public at the offering price set forth on the cover page of the
Prospectus Supplement (the “Offering”).
6
2.2
Over-Allotment
Option.
(a) For the purposes of
covering any over-allotments in connection with the distribution
and sale of the Closing Shares, the Representative is hereby
granted an option (the “Over-Allotment Option”)
to purchase, in the aggregate, up to 484,500 shares of Common Stock
(the “Option
Shares”) with each Option Share to be purchased at the
Share Purchase Price.
(b) In connection with
an exercise of the Over-Allotment Option, the purchase price to be
paid for the Option Shares is equal to the product of the Share
Purchase Price multiplied by the number of Option Shares to be
purchased (the “Option Closing Purchase
Price”).
(c) The Over-Allotment
Option granted pursuant to this Section 2.2 may be exercised by the
Representative as to all (at any time) or any part (from time to
time) of the Option Shares within 45 days after the Execution Date.
An Underwriter will not be under any obligation to purchase any
Option Shares prior to the exercise of the Over-Allotment Option by
the Representative. The Over-Allotment Option granted hereby may be
exercised by the giving of oral notice to the Company from the
Representative, which must be confirmed in writing by overnight
mail or facsimile or other electronic transmission setting forth
the number of Option Shares to be purchased and the date and time
for delivery of and payment for the Option Shares (each, an
“Option Closing
Date”), which will not be later than two (2) full
Business Days after the date of the notice or such other time as
shall be agreed upon by the Company and the Representative, at the
offices of EGS or at such other place (including remotely by
facsimile or other electronic transmission) as shall be agreed upon
by the Company and the Representative. If such delivery and payment
for the Option Shares does not occur on the Closing Date, each
Option Closing Date will be as set forth in the notice. Upon
exercise of the Over-Allotment Option, the Company will become
obligated to convey to the Underwriters, and, subject to the terms
and conditions set forth herein, the Underwriters will become
obligated to purchase, the number of Option Shares specified in
such notice. The Representative may cancel the Over-Allotment
Option at any time prior to the expiration of the Over-Allotment
Option by written notice to the Company
2.3 Deliveries. The Company shall
deliver or cause to be delivered to each Underwriter (if
applicable) the following:
(a) At the Closing
Date, the Closing Shares and, as to each Option Closing Date, if
any, the applicable Option Shares, which shares shall be delivered
via The Depository Trust Company Deposit or Withdrawal at Custodian
system for the accounts of the several Underwriters;
(b) Contemporaneously
herewith and at the Closing Date, a legal opinion of Company
Special Counsel addressed to the Underwriters, including, without
limitation, a negative assurance letter, in form and substance
reasonably satisfactory to the Representative and EGS, and as to
the Closing Date and as to each Option Closing Date, if any, a
bring-down opinion from Company Special Counsel in form and
substance
7
reasonably
satisfactory to the Representative and EGS, and the favorable
opinions of intellectual property legal counsel to the Company,
including, without limitation, a negative assurance letter,
addressed to the Underwriters and in form and substance
satisfactory to the Representative and EGS;
(c) Contemporaneously
herewith, a cold comfort letter, addressed to the Underwriters and
in form and substance satisfactory in all respects to the
Representative from the Company Auditor dated, respectively, as of
the date of this Agreement and a bring-down letter dated as of the
Closing Date and each Option Closing Date, if any;
(d) On the Closing Date
and on each Option Closing Date, the duly executed and delivered
Certificate of the Chief Executive Officer, in form and substance
reasonably satisfactory to the Representative and EGS, to the
effect that, as of the date of this Agreement and as of the
applicable date, the representations and warranties of the Company
contained herein were and are accurate in all material respects,
except for such changes as are contemplated by this Agreement and
except as to representations and warranties that were expressly
limited to a state of facts existing at a time prior to the Closing
Date and each Option Closing Date, and that, as of the applicable
date, the obligations to be performed by the Company hereunder on
or prior thereto have been fully performed in all material
respects;
(e) On the Closing Date
and on each Option Closing Date, the duly executed and delivered
Officer’s Certificate, in form and substance reasonably
satisfactory to the Representative and EGS, certifying to, among
others, the organizational documents and board resolutions relating
to the Offering;
(f) On the Closing Date
and on each Option Closing Date, the duly executed and delivered
Chief Executive Officer Certificate, in form and substance
reasonably satisfactory to the Representative and EGS, certifying
to, among others, certain regulatory matters;
(g) On the Closing Date
and on each Option Closing Date, the duly executed and delivered
Chief Financial Officer’s Certificate (executed by the Chief
Financial Officer, Chief Executive Officer, and Chairman of the
Board of Directors), in form and substance reasonably satisfactory
to the Representative and EGS, certifying to, among others, certain
financial information;
(h) On the Closing Date
and on each and every Option Closing Date, a cash fee payable to
the Representative equal to six percent (6%) of the aggregate gross
proceeds raised in the Offering; and
(i) Contemporaneously
herewith, the duly executed and delivered Lock-Up
Agreements.
8
2.4 Closing Conditions. The
respective obligations of each Underwriter hereunder in connection
with the Closing and each Option Closing Date are subject to the
following conditions being met:
(a) the accuracy in all
material respects when made and on the date in question (other than
representations and warranties of the Company already qualified by
materiality, which shall be true and correct in all respects) of
the representations and warranties of the Company contained herein
(unless as of a specific date therein);
(b) all obligations,
covenants and agreements of the Company required to be performed at
or prior to the date in question shall have been
performed;
(c) the delivery by the
Company of the items set forth in Section 2.3 of this
Agreement;
(d) the Registration
Statement shall be effective on the date of this Agreement and at
each of the Closing Date and each Option Closing Date, if any, no
stop order suspending the effectiveness of the Registration
Statement shall have been issued and no proceedings for that
purpose shall have been instituted or shall be pending or
contemplated by the Commission and any request on the part of the
Commission for additional information shall have been complied with
to the reasonable satisfaction of the Representative;
(e) by the Execution
Date, if required by FINRA, the Underwriters shall have received
clearance from FINRA as to the amount of compensation allowable or
payable to the Underwriters as described in the Registration
Statement;
(f) the Closing Shares
and the Option Shares have been approved for listing on the Trading
Market; and
(g) prior to and on
each of the Closing Date and each Option Closing Date, if any: (i)
there shall have been no material adverse change or development
involving a prospective material adverse change in the condition or
prospects or the business activities, financial or otherwise, of
the Company from the latest dates as of which such condition is set
forth in the Registration Statement, the Prospectus and the
Prospectus Supplement; (ii)
no action suit or
proceeding, at law or in equity, shall have been pending or
threatened against the Company or any Affiliate of the Company
before or by any court or federal or state commission, board or
other administrative agency wherein an unfavorable decision, ruling
or finding may materially adversely affect the business,
operations, prospects or financial condition or income of the
Company, except as set forth in the Registration Statement, the
Prospectus and Prospectus Supplement; (iii) no stop order shall
have been issued under the Securities Act and no proceedings
therefor shall have been initiated or threatened by the Commission;
(iv) the Company has not incurred any material liabilities or
obligations, direct or contingent, nor has it entered into any
material transactions not in the ordinary course of business, other
than pursuant to this Agreement and the transactions referred to
herein; (v) the Company has not paid or declared any dividends or
other
9
distributions of
any kind on any class of its capital stock; (vi) the Company has
not altered its method of accounting; and (vii) the Registration
Statement, Prospectus and the Prospectus Supplement and any
amendments or supplements thereto shall contain all material
statements which are required to be stated therein in accordance
with the Securities Act and the rules and regulations thereunder
and shall conform in all material respects to the requirements of
the Securities Act and the rules and regulations thereunder, and
none of the Registration Statement, the Prospectus nor the
Prospectus Supplement or any amendment or supplement thereto shall
contain any untrue statement of a material fact or omit to state
any material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under
which they were made, not misleading.
ARTICLE
III.
REPRESENTATIONS
AND WARRANTIES
3.1 Representations and Warranties of the
Company. Except as set forth in the Disclosure Schedules,
which Disclosure Schedules shall be deemed a part hereof and shall
qualify any representation or otherwise made herein to the extent
of the disclosure contained in the corresponding section of the
Disclosure Schedules, the Company represents and warrants to the
Underwriters as of the Execution Date, as of the Closing Date and
as of each Option Closing Date, if any, as follows:
(a) Subsidiaries. Except as set
forth on Schedule
3.1(a), all of the direct and indirect Subsidiaries of the
Company are set forth in the SEC Reports. The Company owns,
directly or indirectly, all of the capital stock or other equity
interests of each Subsidiary which it owns, free and clear of any
Liens, and all of the issued and outstanding shares of capital
stock of each Subsidiary are validly issued and are fully paid,
non-assessable and free of preemptive and similar rights to
subscribe for or purchase securities (except as set forth on
Schedule 3.1(a)). If the Company has no Subsidiaries, all other
references to the Subsidiaries or any of them in the Transaction
Documents shall be disregarded.
(b) Organization and Qualification.
The Company and each of the Subsidiaries is an entity duly
incorporated or otherwise organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation or
organization, with the requisite power and authority to own and use
its properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in violation
nor default of any of the provisions of its respective certificate
or articles of incorporation, bylaws or other organizational or
charter documents, except where such violation or default, as the
case may be, would not have or reasonably be expected to result in,
a Material Adverse Effect. Each of the Company and the Subsidiaries
is duly qualified to conduct business and is in good standing as a
foreign corporation or other entity in each jurisdiction in which
the nature of the business conducted or property owned by it makes
such qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, could not have
or reasonably be expected to result in a Material Adverse Effect
and no
10
Proceeding has been
instituted in any such jurisdiction revoking, limiting or
curtailing or seeking to revoke, limit or curtail such power and
authority or qualification.
(c) Authorization; Enforcement. The
Company has the requisite corporate power and authority to enter
into and to consummate the transactions contemplated by this
Agreement and each of the other Transaction Documents to which it
is a party and otherwise to carry out its obligations hereunder and
thereunder. The execution and delivery of this Agreement and each
of the other Transaction Documents by the Company and the
consummation by it of the transactions contemplated hereby and
thereby have been duly authorized by all necessary action on the
part of the Company and no further action is required by the
Company, the Board of Directors or the Company’s stockholders
in connection herewith or therewith other than in connection with
the Required Approvals. This Agreement and each other Transaction
Document to which the Company is a party has been (or upon delivery
will have been) duly executed by the Company and, when delivered in
accordance with the terms hereof and thereof, will constitute the
valid and binding obligation of the Company enforceable against the
Company in accordance with its terms, except (i) as limited by
general equitable principles and applicable bankruptcy, insolvency,
reorganization, moratorium and other laws of general application
affecting enforcement of creditors’ rights generally, (ii) as
limited by laws relating to the availability of specific
performance, injunctive relief or other equitable remedies and
(iii) insofar as indemnification and contribution provisions may be
limited by applicable law.
(d) No Conflicts. The execution,
delivery and performance by the Company of this Agreement and the
other Transaction Documents to which it is a party, the issuance
and sale of the Public Shares and the consummation by it of the
transactions contemplated hereby and thereby do not and will not
(i) conflict with or violate any provision of the Company’s
or any Subsidiary’s certificate or articles of incorporation,
bylaws or other organizational or charter documents, or (ii)
conflict with, or constitute a default (or an event that with
notice or lapse of time or both would become a default) under,
result in the creation of any Lien upon any of the properties or
assets of the Company or any Subsidiary, or give to others any
rights of termination, amendment, anti-dilution or similar
adjustments, acceleration or cancellation (with or without notice,
lapse of time or both) of, any agreement, credit facility, debt or
other instrument (evidencing a Company or Subsidiary debt or
otherwise) or other understanding to which the Company or any
Subsidiary is a party or by which any property or asset of the
Company or any Subsidiary is bound or affected, or (iii) subject to
the Required Approvals, conflict with or result in a violation of
any law, rule, regulation, order, judgment, injunction, decree or
other restriction of any court or governmental authority to which
the Company or a Subsidiary is subject (including federal and state
securities laws and regulations), or by which any property or asset
of the Company or a Subsidiary is bound or affected; except in the
case of each of clauses (ii) and (iii), such as could not have or
reasonably be expected to result in a Material Adverse
Effect.
(e) Filings, Consents and
Approvals. The Company is not required to obtain any
consent, waiver, authorization or order of, give any notice to, or
make any filing or registration with, any court or other federal,
state, local or other governmental authority or
11
other Person in
connection with the execution, delivery and performance by the
Company of the Transaction Documents, other than: (i) the filing
with the Commission of the Prospectus Supplement, (ii) such
consents, approvals, authorizations, orders and registrations or
qualifications as may be required by FINRA and the Trading
Market, (iii) approval of
the Board of Directors of the terms and conditions of this
Agreement, and (iv) such filings as are
required to be made under applicable state securities laws
(collectively, the “Required
Approvals”).
(f) Registration Statement. The
Company has filed with the Commission the Registration Statement
under the Securities Act, which became effective on July 2, 2018
(the “Effective
Date”), for the registration under the Securities Act
of the Public Shares. At the time of such filing, the Company met
the requirements of Form S-3 under the Securities Act. The
Registration Statement meets the requirements set forth in Rule
415(a)(1)(x) under the Securities Act and complies with said Rule
and the Prospectus Supplement will meet the requirements set forth
in Rule 424(b). The Company has advised the Representative of all
further information (financial and other) with respect to the
Company required to be set forth therein in the Registration
Statement and Prospectus Supplement. Any reference in this
Agreement to the Registration Statement, the Prospectus or the
Prospectus Supplement shall be deemed to refer to and include the
documents incorporated by reference therein pursuant to Item 12 of
Form S-3 which were filed under the Exchange Act, on or before the
date of this Agreement, or the issue date of the Prospectus or the
Prospectus Supplement, as the case may be; and any reference in
this Agreement to the terms “amend,”
“amendment” or “supplement” with respect to
the Registration Statement, the Prospectus or the Prospectus
Supplement shall be deemed to refer to and include the filing of
any document under the Exchange Act after the date of this
Agreement, or the issue date of the Prospectus or the Prospectus
Supplement, as the case may be, deemed to be incorporated therein
by reference. All references in this Agreement to financial
statements and schedules and other information which is
“contained,” “included,”
“described,” “referenced,” “set
forth” or “stated” in the Registration Statement,
the Prospectus or the Prospectus Supplement (and all other
references of like import) shall be deemed to mean and include all
such financial statements and schedules and other information which
is or is deemed to be incorporated by reference in the Registration
Statement, the Prospectus or the Prospectus Supplement, as the case
may be. No stop order suspending the effectiveness of the
Registration Statement or the use of the Prospectus or the
Prospectus Supplement has been issued, and no proceeding for any
such purpose is pending or has been initiated or, to the Company's
knowledge, is threatened by the Commission. For purposes of this
Agreement, “free
writing prospectus” has the meaning set forth in Rule
405 under the Securities Act. The Company will not, without the
prior consent of the Representative, prepare, use or refer to, any
free writing prospectus.
12
(g) Issuance of Public Shares. The
Public Shares are duly authorized and, when issued and paid for in
accordance with the applicable Transaction Documents, will be duly
and validly issued, fully paid and nonassessable, free and clear of
all Liens imposed by the Company. The holder of the Public Shares
will not be subject to personal liability by reason of being such
holders. The Public Shares are not and will not be subject to the
preemptive rights of any holders of any security of the Company or
similar contractual rights granted by the Company. All corporate
action required to be taken for the authorization, issuance and
sale of the Public Shares has been duly and validly taken. The
Public Shares conform in all material respects to all statements
with respect thereto contained in the Registration
Statement.
(h) Capitalization. The
capitalization of the Company is as set forth in the SEC Reports.
The Company has not issued any capital stock since its most
recently filed periodic report under the Exchange Act, other than
pursuant to the exercise of employee stock options under the
Company’s stock option plans, the issuance of shares of
Common Stock to employees pursuant to the Company’s employee
stock purchase plans and pursuant to the conversion and/or exercise
of Common Stock Equivalents outstanding as of the date of the most
recently filed periodic report under the Exchange Act. No Person
has any right of first refusal, preemptive right, right of
participation, or any similar right to participate in the
transactions contemplated by the Transaction Documents. Except as a
result of the purchase and sale of the Public Shares, there are no
outstanding options, warrants, scrip rights to subscribe to, calls
or commitments of any character whatsoever relating to, or
securities, rights or obligations convertible into or exercisable
or exchangeable for, or giving any Person any right to subscribe
for or acquire, any shares of Common Stock, or contracts,
commitments, understandings or arrangements by which the Company or
any Subsidiary is or may become bound to issue additional shares of
Common Stock or Common Stock Equivalents, except as set forth on
Schedule 3.1(g). The issuance and sale of the Public Shares will
not obligate the Company to issue shares of Common Stock or other
securities to any Person (other than the Underwriters). There are
no outstanding securities or instruments of the Company or any
Subsidiary with any provision that adjusts the exercise,
conversion, exchange or reset price of such security or instrument
upon an issuance of securities by the Company or any Subsidiary
which will be triggered by the sale of the Public Shares. All of
the outstanding shares of capital stock of the Company issued on or
after October 9, 2008 (such date, the “Business Combination
Date”) are duly authorized, validly issued, fully paid
and nonassessable, have been issued in compliance with all federal
and state securities laws, and none of such outstanding shares was
issued in violation of any preemptive rights or similar rights to
subscribe for or purchase securities. The authorized shares of the
Company conform in all material respects to all statements relating
thereto contained in the Registration Statement, the Prospectus and
the Prospectus Supplement. Since the Business Combination Date,
offers and sales of the Company’s securities were at all
relevant times either registered under the Securities Act and the
applicable state securities or Blue Sky laws or, based in part on
the representations and warranties of the purchasers, exempt from
such registration requirements. No further approval or
authorization of any stockholder, the Board of Directors or others
is required for the issuance and sale of the Public Shares. There
are no
13
stockholders
agreements, voting agreements or other similar agreements with
respect to the Company’s capital stock to which the Company
is a party or, to the knowledge of the Company, between or among
any of the Company’s stockholders.
(i) SEC Reports; Financial
Statements. The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by the
Company under the Securities Act and the Exchange Act, including
pursuant to Section 13(a) or 15(d) thereof, for the two years
preceding the date hereof (or such shorter period as the Company
was required by law or regulation to file such material) (the
foregoing materials, including the exhibits thereto and documents
incorporated by reference therein, together with the Registration
Statement, the Preliminary Prospectus, the Prospectus and the
Prospectus Supplement, being collectively referred to herein as the
“SEC
Reports”) on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports
prior to the expiration of any such extension, or the failure to
timely file such SEC Report(s) did not have an effect on the
Company’s ability to use Form S-3. As of their respective
dates, the SEC Reports complied in all material respects with the
requirements of the Securities Act and the Exchange Act, as
applicable, and none of the SEC Reports, when filed, contained any
untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make
the statements therein, in the light of the circumstances under
which they were made, not misleading. The financial statements of
the Company included in the SEC Reports comply in all material
respects with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at
the time of filing. Such financial statements have been prepared in
accordance with United States generally accepted accounting
principles applied on a consistent basis during the periods
involved (“GAAP”), except as may be
otherwise specified in such financial statements or the notes
thereto and except that unaudited financial statements may not
contain all footnotes required by GAAP, and fairly present in all
material respects the financial position of the Company and its
consolidated Subsidiaries as of and for the dates thereof and the
results of operations and cash flows for the periods then ended,
subject, in the case of unaudited statements, to normal,
immaterial, year-end audit adjustments. The agreements and
documents described in the Registration Statement, the Prospectus,
the Prospectus Supplement and the SEC Reports conform to the
descriptions thereof contained therein and there are no agreements
or other documents required by the Securities Act and the rules and
regulations thereunder to be described in the Registration
Statement, the Prospectus, the Prospectus Supplement or the SEC
Reports or to be filed with the Commission as exhibits to the
Registration Statement, that have not been so described or filed.
Each agreement or other instrument (however characterized or
described) to which the Company is a party or by which it is or may
be bound or affected and (i) that is referred to in the
Registration Statement, the Prospectus, the Prospectus Supplement,
or the SEC Reports, or (ii) is material to the Company’s
business, has been duly authorized and validly executed by the
Company, is in full force and effect in all material respects and
is enforceable against the Company, and, to the Company’s
knowledge, the other parties thereto, in accordance with its terms,
except (x) as such enforceability may be limited by bankruptcy,
insolvency, reorganization or similar laws affecting
creditors’ rights generally, (y) as enforceability of any
indemnification or contribution provision may be limited under the
federal and state securities laws, and
14
(z) that the remedy of
specific performance and injunctive and other forms of equitable
relief may be subject to the equitable defenses and to the
discretion of the court before which any proceeding therefore may
be brought. None of such agreements or instruments has been
assigned by the Company, and neither the Company nor, to the best
of the Company’s knowledge, any other party is in default
thereunder and, to the best of the Company’s knowledge, no
event has occurred that, with the lapse of time or the giving of
notice, or both, would constitute a default thereunder. To the best
of the Company’s knowledge, performance by the Company of the
material provisions of such agreements or instruments will not
result in a violation of any existing applicable law, rule,
regulation, judgment, order or decree of any governmental agency or
court, domestic or foreign, having jurisdiction over the Company or
any of its assets or businesses, including, without limitation,
those relating to environmental laws and regulations, except for
violations which would not, individually or in the aggregate,
reasonably be expected to result in a Material Adverse
Effect.
(j) Material Changes; Undisclosed Events,
Liabilities or Developments. Since the date of the latest
audited financial statements included within the SEC Reports,
except as specifically disclosed in a subsequent SEC Report filed
prior to the date hereof, (i) there has been no event, occurrence
or development that has had or that could reasonably be expected to
result in a Material Adverse Effect, (ii) the Company has not
incurred any liabilities (contingent or otherwise) other than (A)
trade payables and accrued expenses incurred in the ordinary course
of business consistent with past practice and (B) liabilities not
required to be reflected in the Company’s financial
statements pursuant to GAAP or disclosed in filings made with the
Commission, (iii) the Company has not altered its method of
accounting, (iv) the Company has not declared or made any dividend
or distribution of cash or other property to its stockholders or
purchased, redeemed or made any agreements to purchase or redeem
any shares of its capital stock, (v) the Company has not issued any
equity securities to any officer, director or Affiliate, except
pursuant to existing Company stock option or equity plans and (vi)
no officer or director of the Company has resigned from any
position with the Company. The Company does not have pending before
the Commission any request for confidential treatment of
information. Except for the issuance of the Public Shares
contemplated by this Agreement, no event, liability, fact,
circumstance, occurrence or development has occurred or exists or
is reasonably expected to occur or exist with respect to the
Company or its Subsidiaries or their respective businesses,
prospects, properties, operations, assets or financial condition
that would be required to be disclosed by the Company under
applicable securities laws at the time this representation is made
or deemed made that has not been publicly disclosed at least one
(1) Trading Day prior to the date that this representation is made.
Unless otherwise disclosed in an SEC Report filed prior to the date
hereof, the Company has not: (i) issued any
securities or incurred any liability or obligation, direct or
contingent, for borrowed money; or (ii) declared or paid any
dividend or made any other distribution on or in respect to its
capital stock.
(k) Litigation. There is no action,
suit, inquiry, notice of violation, proceeding or investigation
pending or, to the knowledge of the Company, threatened against or
affecting the Company, any Subsidiary or any of their respective
properties before or by
15
any
court, arbitrator, governmental or administrative agency or
regulatory authority (federal, state, county, local or foreign)
(collectively, an “Action”) which (i)
adversely affects or challenges the legality, validity or
enforceability of any of the Transaction Documents or the Public
Shares or (ii) could, if there were an unfavorable decision, have
or reasonably be expected to result in a Material Adverse Effect.
Except as set forth on Schedule 3.1(j), neither the Company nor any
Subsidiary, nor, to the knowledge of the Company, any director or
officer thereof, is or has been the subject of any Action involving
a claim of violation of or liability under federal or state
securities laws or a claim of breach of fiduciary duty. There has
not been, since the Business Combination Date, and to the knowledge
of the Company, there is not pending or contemplated, any
investigation by the Commission involving the Company or any
current or former director or officer of the Company. The
Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the
Company or any Subsidiary under the Exchange Act or the Securities
Act.
(l) Labor Relations. No labor
dispute exists or, to the knowledge of the Company, is imminent
with respect to any of the employees of the Company, which could
reasonably be expected to result in a Material Adverse Effect. None
of the Company’s or its Subsidiaries’ employees is a
member of a union that relates to such employee’s
relationship with the Company or such Subsidiary, and neither the
Company nor any of its Subsidiaries is a party to a collective
bargaining agreement, and the Company and its Subsidiaries believe
that their relationships with their employees are good. To the
knowledge of the Company, no executive officer of the Company or
any Subsidiary, is, or is now expected to be, in violation of any
material term of any employment contract, confidentiality,
disclosure or proprietary information agreement or non-competition
agreement, or any other contract or agreement or any restrictive
covenant in favor of any third party, and the continued employment
of each such executive officer does not subject the Company or any
of its Subsidiaries to any liability with respect to any of the
foregoing matters. The Company and its Subsidiaries are in
compliance with all U.S. federal, state, local and foreign laws and
regulations relating to employment and employment practices, terms
and conditions of employment and wages and hours, except where the
failure to be in compliance could not, individually or in the
aggregate, reasonably be expected to have a Material Adverse
Effect.
(m) Compliance. Neither the Company
nor any Subsidiary: (i) is in default under or in violation of (and
no event has occurred that has not been waived that, with notice or
lapse of time or both, would result in a default by the Company or
any Subsidiary under), nor has the Company or any Subsidiary
received notice of a claim that it is in default under or that it
is in violation of, any indenture, loan or credit agreement or any
other agreement or instrument to which it is a party or by which it
or any of its properties is bound (whether or not such default or
violation has been waived), (ii) is in violation of any judgment,
decree or order of any court, arbitrator or other governmental
authority or (iii) is or has been in violation of any statute,
rule, ordinance or regulation of any governmental authority,
including without limitation all foreign, federal, state and local
laws relating to taxes, environmental protection, occupational
health and safety, product quality and safety
16
and
employment and labor matters, except in each case as could not have
or reasonably be expected to result in a Material Adverse
Effect.
(n) Regulatory Permits. The Company
and the Subsidiaries possess all certificates, authorizations and
permits issued by the appropriate federal, state, local or foreign
regulatory authorities necessary to conduct their respective
businesses as described in the SEC Reports, except where the
failure to possess such permits could not reasonably be expected to
result in a Material Adverse Effect (each, a “Material Permit”), and
neither the Company nor any Subsidiary has received any notice of
proceedings relating to the revocation or modification of any
Material Permit. The disclosures in the Registration Statement
concerning the effects of Federal, State, local and all foreign
regulation on the Company’s business as currently
contemplated are correct in all material respects.
(o) Title to Assets. The Company
and the Subsidiaries have good and marketable title in fee simple
to, or have valid and marketable rights to lease or otherwise use,
all real property and all personal property that is material to the
business of the Company and the Subsidiaries, in each case free and
clear of all Liens, except for (i) Liens as do not materially
affect the value of such property and do not materially interfere
with the use made and proposed to be made of such property by the
Company and the Subsidiaries, (ii) Liens for the payment of
federal, state or other taxes, for which appropriate reserves have
been made therefor in accordance with GAAP, and the payment of
which is neither delinquent nor subject to penalties, and (iii)
Liens disclosed on Schedule 3.1(o). Any real property and
facilities held under lease by the Company and the Subsidiaries are
held by them under valid, subsisting and enforceable leases with
which the Company and the Subsidiaries are in compliance, except
where the failure to be in compliance could not, individually or in
the aggregate, reasonably be expected to have a Material Adverse
Effect.
(p) Intellectual Property. The
Company and the Subsidiaries have, or have rights to use, all
patents, patent applications, trademarks, trademark applications,
service marks, trade names, trade secrets, inventions, copyrights,
licenses and other intellectual property rights and similar rights
necessary or required for use in connection with their respective
businesses as described in the SEC Reports and which the failure to
do so could have a Material Adverse Effect (collectively, the
“Intellectual
Property Rights”). None of, and neither the Company
nor any Subsidiary has received a notice (written or otherwise)
that any of, the Intellectual Property Rights has expired,
terminated or been abandoned, or is expected to expire or terminate
or be abandoned, within two (2) years from the date of this
Agreement, except for expirations, terminations, or abandonments
which would not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. Neither the Company nor
any Subsidiary has received, since the date of the latest audited
financial statements included within the SEC Reports, a written
notice of a claim or otherwise has any knowledge that the
Intellectual Property Rights violate or infringe upon the rights of
any Person, or that the Company or any Subsidiary is engaged in any
other activity that violates or infringes upon the rights of any
Person. To the knowledge of the Company, all such Intellectual
Property Rights are enforceable and there is no existing
infringement by another Person of any of the Intellectual Property
Rights. The Company
17
and its
Subsidiaries have taken reasonable security measures to protect the
secrecy, confidentiality and value of all of their intellectual
properties, except where failure to do so could not, individually
or in the aggregate, reasonably be expected to have a Material
Adverse Effect.
(q) Insurance. The Company and the
Subsidiaries are insured by insurers of recognized financial
responsibility against such losses and risks and in such amounts as
are prudent and customary in the businesses in which the Company
and the Subsidiaries are engaged, including, but not limited to,
directors and officers insurance coverage. Neither the Company nor
any Subsidiary has any reason to believe that it will not be able
to renew its existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business without a significant
increase in cost.
(r) Transactions With Affiliates and
Employees. Except as set forth in the SEC Reports, none of
the officers or directors of the Company or any Subsidiary and, to
the knowledge of the Company, none of the employees of the Company
or any Subsidiary is presently a party to any transaction with the
Company or any Subsidiary (other than for services as employees,
officers and directors), including any contract, agreement or other
arrangement providing for the furnishing of services to or by,
providing for rental of real or personal property to or from,
providing for the borrowing of money from or lending of money to or
otherwise requiring payments to or from, any officer, director or
such employee or, to the knowledge of the Company, any entity in
which any officer, director, or any such employee has a substantial
interest or is an officer, director, trustee, stockholder, member
or partner, in each case in excess of $120,000 other than for (i)
payment of salary or consulting fees for services rendered, (ii)
reimbursement for expenses incurred on behalf of the Company and
(iii) other employee benefits, including stock option agreements
under any stock option plan of the Company.
(s) Xxxxxxxx-Xxxxx; Internal Accounting
Controls. The Company and the Subsidiaries are in compliance
with any and all applicable requirements of the Xxxxxxxx- Xxxxx Act
of 2002 that are effective as of the date hereof, and any and all
applicable rules and regulations promulgated by the Commission
thereunder that are effective as of the date hereof and as of the
Closing Date. The Company and the Subsidiaries maintain a system of
internal accounting controls sufficient to provide reasonable
assurance that: (i) transactions are executed in accordance with
management’s general or specific authorizations, (ii)
transactions are recorded as necessary to permit preparation of
financial statements in conformity with GAAP and to maintain asset
accountability, (iii) access to assets is permitted only in
accordance with management’s general or specific
authorization, and (iv) the recorded accountability for assets is
compared with the existing assets at reasonable intervals and
appropriate action is taken with respect to any differences. The
Company and the Subsidiaries have established disclosure controls
and procedures (as defined in Exchange Act Rules 13a-15(e) and
15d-15(e)) for the Company and the Subsidiaries and designed such
disclosure controls and procedures to provide reasonable assurance
that information required to be disclosed by the Company in the
reports it files or submits under the Exchange Act is recorded,
processed, summarized and reported,
18
within
the time periods specified in the Commission’s rules and
forms. The Company’s certifying officers have evaluated the
effectiveness of the disclosure controls and procedures of the
Company and the Subsidiaries as of the end of the period covered by
the most recently filed periodic report under the Exchange Act
(such date, the “Evaluation Date”). The Company
presented in its most recently filed periodic report under the
Exchange Act the conclusions of the certifying officers about the
effectiveness of the disclosure controls and procedures based on
their evaluations as of the Evaluation Date. Since the Evaluation
Date, there have been no changes in the internal control over
financial reporting (as such term is defined in the Exchange Act)
of the Company and its Subsidiaries that have materially affected,
or is reasonably likely to materially affect, the internal control
over financial reporting of the Company and its
Subsidiaries.
(t) Certain Fees. Except as set
forth in the Prospectus Supplement, no brokerage or finder’s
fees or commissions are or will be payable by the Company, any
Subsidiary or Affiliate of the Company to any broker, financial
advisor or consultant, finder, placement agent, investment banker,
bank or other Person with respect to the transactions contemplated
by the Transaction Documents. To the Company’s knowledge,
there are no other arrangements, agreements or understandings of
the Company or, to the Company’s knowledge, any of its
stockholders that may affect the Underwriters’ compensation,
as determined by FINRA. Except for payments made by the Company to
the Representative, pursuant to that certain Placement Agency
Agreement, dated July 24, 2020, between the Company and the
Representative, and to the Representative and Aegis Capital Corp.,
pursuant to that certain Underwriting Agreement, dated December 28,
2020, among the Company, Aegis Capital Corp. and the
Representative, the Company has not made any direct or indirect
payments (in cash, securities or otherwise) to: (i) any person, as
a finder’s fee, consulting fee or otherwise, in consideration
of such person raising capital for the Company or introducing to
the Company persons who raised or provided capital to the Company;
(ii) any FINRA member; or (iii) any person or entity that has any
direct or indirect affiliation or association with any FINRA
member, within the twelve months prior to the Execution Date. None
of the net proceeds of the Offering will be paid by the Company to
any participating FINRA member or its affiliates, except as
specifically authorized herein.
(u) Investment Company. The Company
is not, and is not an Affiliate of, and immediately after receipt
of payment for the Public Shares will not be or be an Affiliate of,
an “investment company” within the meaning of the
Investment Company Act of 1940, as amended. The Company shall
conduct its business in a manner so that it will not become an
“investment company” subject to registration under the
Investment Company Act of 1940, as amended.
(v) Registration Rights. No Person
has any right to cause the Company or any Subsidiary to effect the
registration under the Securities Act of any securities of the
Company or any Subsidiary that has not been waived or extended as
of the date of this Agreement.
19
(w) Listing and Maintenance
Requirements. The Common Stock is registered pursuant to
Section 12(b) of the Exchange Act, and the Company has taken no
action designed to, or which to its knowledge is likely to have the
effect of, terminating the registration of the Common Stock under
the Exchange Act nor has the Company received any notification that
the Commission is contemplating terminating such registration. The
Company has not, in the 12 months preceding the date hereof,
received notice from any Trading Market on which the Common Stock
is or has been listed or quoted to the effect that the Company is
not in compliance with the listing or maintenance requirements of
such Trading Market. The Company is, and has no reason to believe
that it will not in the foreseeable future continue to be, in
compliance with all such listing and maintenance requirements. The
Common Stock is currently eligible for electronic transfer through
the Depository Trust Company or another established clearing
corporation and the Company is current in payment of the fees of
the Depository Trust Company (or such other established clearing
corporation) in connection with such electronic
transfer.
(x) Application of Takeover
Protections. The Company and the Board of Directors have
taken all necessary action, if any, in order to render inapplicable
any control share acquisition, business combination, poison pill
(including any distribution under a rights agreement) or other
similar anti-takeover provision under the Company’s
certificate of incorporation (or similar charter documents) or the
laws of its state of incorporation that is or could become
applicable as a result of the Underwriters and the Company
fulfilling their obligations or exercising their rights under the
Transaction Documents.
(y) Disclosure; 10b-5. The
Registration Statement (and any further documents to be filed with
the Commission) contains all exhibits and schedules as required by
the Securities Act. Each of the Registration Statement and any
post-effective amendment thereto, if any, at the time it became
effective, complied in all material respects with the Securities
Act and the Exchange Act and the applicable rules and regulations
under the Securities Act and did not and, as amended or
supplemented, if applicable, will not, contain any untrue statement
of a material fact or omit to state a material fact required to be
stated therein or necessary to make the statements therein not
misleading. The Prospectus and any Prospectus Supplement, each as
of its respective date, comply in all material respects with the
Securities Act and the Exchange Act and the applicable rules and
regulations. Each of the Prospectus and the Prospectus Supplement,
as amended or supplemented, did not and will not contain as of the
date thereof any untrue statement of a material fact or omit to
state a material fact necessary in order to make the statements
therein, in light of the circumstances under which they were made,
not misleading. The SEC Reports, when they were filed with the
Commission, conformed in all material respects to the requirements
of the Exchange Act and the applicable rules and regulations, and
none of such documents, when they were filed with the Commission,
contained any untrue statement of a material fact or omitted to
state a material fact necessary to make the statements therein
(with respect to the SEC Reports incorporated by reference in the
Prospectus or Prospectus Supplement), in light of the circumstances
under which they were made not misleading; and any further
documents so filed and incorporated by reference in the Prospectus
or Prospectus Supplement, when such documents are filed with the
Commission, will conform in all material respects to the
requirements of the Exchange Act
20
and the
applicable rules and regulations, as applicable, and will not
contain any untrue statement of a material fact or omit to state a
material fact necessary to make the statements therein, in light of
the circumstances under which they were made not misleading. No
post- effective amendment to the Registration Statement reflecting
any facts or events arising after the date thereof which represent,
individually or in the aggregate, a fundamental change in the
information set forth therein is required to be filed with the
Commission. There are no documents required to be filed with the
Commission in connection with the transaction contemplated hereby
that (x) have not been filed as required pursuant to the Securities
Act or (y) will not be filed within the requisite time period.
There are no contracts or other documents required to be described
in the Prospectus or Prospectus Supplement, or to be filed as
exhibits or schedules to the Registration Statement, which have not
been described or filed as required. The press releases
disseminated by the Company during the twelve months preceding the
date of this Agreement taken as a whole do not contain any untrue
statement of a material fact or omit to state a material fact
required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they
were made and when made, not misleading.
(z) No Integrated Offering. Neither
the Company, nor any of its Affiliates, nor any Person acting on
its or their behalf has, directly or indirectly, made any offers or
sales of any security or solicited any offers to buy any security,
under circumstances that would cause this offering of the Public
Shares to be integrated with prior offerings by the Company for
purposes of any applicable shareholder approval provisions of any
Trading Market on which any of the securities of the Company are
listed or designated.
(aa)
Solvency. Based on
the consolidated financial condition of the Company as of the
Closing Date, after giving effect to the receipt by the Company of
the proceeds from the sale of the Public Shares hereunder, (i) the
fair saleable value of the Company’s assets exceeds the
amount that will be required to be paid on or in respect of the
Company’s existing debts and other liabilities (including
known contingent liabilities) as they mature, (ii)
the Company’s
assets do not constitute unreasonably small capital to carry on its
business as now conducted and as proposed to be conducted including
its capital needs taking into account the particular capital
requirements of the business conducted by the Company, consolidated
and projected capital requirements and capital availability
thereof, and (iii) the current cash flow of the Company, together
with the proceeds the Company would receive, were it to liquidate
all of its assets based on the fair saleable value of such assets,
after taking into account all anticipated uses of the cash, would
be sufficient to pay all amounts on or in respect of its
liabilities when such amounts are required to be paid. The Company
does not intend to incur debts beyond its ability to pay such debts
as they mature (taking into account the timing and amounts of cash
to be payable on or in respect of its debt). The Company has no
knowledge of any facts or circumstances which lead it to believe
that it will file for reorganization or liquidation under the
bankruptcy or reorganization laws of any jurisdiction within one
year from the Closing Date. The SEC Reports sets forth as of the
date hereof all outstanding secured and unsecured Indebtedness of
the Company or any Subsidiary, or for which the Company or any
Subsidiary has commitments.
21
(bb)
Tax Status. Except
for matters that would not, individually or in the aggregate, have
or reasonably be expected to result in a Material Adverse Effect,
the Company and its Subsidiaries each (i) has made or filed all
United States federal, state and local income and all foreign
income and franchise tax returns, reports and declarations required
by any jurisdiction to which it is subject, (ii) has paid all taxes
and other governmental assessments and charges that are material in
amount, shown or determined to be due on such returns, reports and
declarations and (iii) has set aside on its books provision
reasonably adequate for the payment of all material taxes for
periods subsequent to the periods to which such returns, reports or
declarations apply. There are no unpaid taxes in any material
amount claimed to be due by the taxing authority of any
jurisdiction, and the officers of the Company or of any Subsidiary
know of no basis for any such claim. The provisions for taxes
payable, if any, shown on the financial statements filed with or as
part of the Registration Statement are sufficient for all accrued
and unpaid taxes, whether or not disputed, and for all periods to
and including the dates of such consolidated financial statements.
The term “taxes” mean all federal, state, local,
foreign, and other net income, gross income, gross receipts, sales,
use, ad valorem, transfer, franchise, profits, license, lease,
service, service use, withholding, payroll, employment, excise,
severance, stamp, occupation, premium, property, windfall profits,
customs, duties or other taxes, fees, assessments, or charges of
any kind whatsoever, together with any interest and any penalties,
additions to tax, or additional amounts with respect thereto. The
term “returns” means all returns, declarations,
reports, statements, and other documents required to be filed in
respect to taxes.
(cc)
Foreign Corrupt
Practices. Neither the Company nor any Subsidiary, nor to
the knowledge of the Company or any Subsidiary, any agent or other
person acting on behalf of the Company or any Subsidiary, has (i)
directly or indirectly, used any funds for unlawful contributions,
gifts, entertainment or other unlawful expenses related to foreign
or domestic political activity, (ii) made any unlawful payment to
foreign or domestic government officials or employees or to any
foreign or domestic political parties or campaigns from corporate
funds, (iii) failed to disclose fully any contribution made by the
Company or any Subsidiary (or made by any person acting on its
behalf of which the Company is aware) which is in violation of law,
or (iv) violated in any material respect any provision of FCPA. The
Company has taken reasonable steps to ensure that its accounting
controls and procedures are sufficient to cause the Company to
comply in all material respects with the FCPA.
(dd)
Accountants. To the
knowledge and belief of the Company, the Company Auditor (i) is an
independent registered public accounting firm as required by the
Exchange Act and (ii) shall express its opinion with respect to the
financial statements to be included in the Company’s Annual
Report for the fiscal year ending February 28, 2021. The Company
Auditor has not, during the periods covered by the financial
statements included in the Prospectus and the Prospectus
Supplement, provided to the Company any non-audit services, as such
term is used in Section 10A(g) of the Exchange Act.
(ee)
[Intentionally Removed].
22
(ff)
Office of Foreign Assets
Control. Neither the Company nor any Subsidiary nor, to the
Company's knowledge, any director, officer, agent, employee or
affiliate of the Company or any Subsidiary is currently subject to
any U.S. sanctions administered by the Office of Foreign Assets
Control of the U.S. Treasury Department.
(gg)
U.S. Real Property Holding
Corporation. The Company is not and has never been a U.S.
real property holding corporation within the meaning of Section 897
of the Internal Revenue Code of 1986, as amended, and the Company
shall so certify upon the Representative’s
request.
(hh)
Bank Holding Company
Act. Neither the Company nor any of its Subsidiaries or
Affiliates is subject to the Bank Holding Company Act of 1956, as
amended (the “BHCA”) and to regulation
by the Board of Governors of the Federal Reserve System (the
“Federal
Reserve”).
Neither the Company nor any of its Subsidiaries or Affiliates owns
or controls, directly or indirectly, five percent (5%) or more of
the outstanding shares of any class of voting securities or
twenty-five percent (25%) or more of the total equity of a bank or
any entity that is subject to the BHCA and to regulation by the
Federal Reserve. Neither the Company nor any of its Subsidiaries or
Affiliates exercises a controlling influence over the management or
policies of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve.
(ii)
Money Laundering.
The operations of the Company and its Subsidiaries are and have
been conducted at all times in compliance with applicable financial
record-keeping and reporting requirements of the Currency and
Foreign Transactions Reporting Act of 1970, as amended, applicable
money laundering statutes and applicable rules and regulations
thereunder (collectively, the “Money Laundering Laws”),
and no action, suit or proceeding by or before any court or
governmental agency, authority or body or any arbitrator involving
the Company or any Subsidiary with respect to the Money Laundering
Laws is pending or, to the knowledge of the Company or any
Subsidiary, threatened.
(jj)
D&O
Questionnaires. To the Company’s knowledge, all
information contained in the questionnaires completed by each of
the Company’s directors and officers immediately prior to the
Offering as well as in the Lock-Up Agreement provided to the
Underwriters is true and correct in all respects and the Company
has not become aware of any information which would cause the
information disclosed in such questionnaires become inaccurate and
incorrect in any material respect.
(kk)
FINRA Affiliation.
No officer or director of the Company, or to the knowledge of the
Company, any beneficial owner of 5% or more of the Company’s
unregistered securities has any direct or indirect affiliation or
association with any FINRA member (as determined in accordance with
the rules and regulations of FINRA) that is participating in the
Offering. The Company will advise the Representative and
EGS, during the 12 month
period following the Closing Date, if it learns that any officer,
director or owner of 10% or more of the Company’s outstanding
shares of Common Stock or Common Stock Equivalents is or becomes an
affiliate or associated person of a FINRA member firm.
23
(ll)
Officers’
Certificate. Any certificate signed by any duly authorized
officer of the Company and delivered to the Representative or EGS
shall be deemed a representation and warranty by the Company to the
Underwriters as to the matters covered thereby.
(mm)
Board of Directors.
The Board of Directors is comprised of the persons set forth in the
SEC Reports. The qualifications of the persons serving as board
members and the overall composition of the Board of Directors
comply with the Xxxxxxxx-Xxxxx Act of 2002 and the rules
promulgated thereunder applicable to the Company and the rules of
the Trading Market. At least one member of the Board of Directors
qualifies as a “financial expert” as such term is
defined under the Xxxxxxxx-Xxxxx Act of 2002 and the rules
promulgated thereunder and the rules of the Trading Market. In
addition, at least a majority of the persons serving on the Board
of Directors qualify as “independent” as defined under
the rules of the Trading Market.
(nn)
Environmental Laws.
The Company and its Subsidiaries (i) are in compliance with all
federal, state, local and foreign laws relating to pollution or
protection of human health or the environment (including ambient
air, surface water, groundwater, land surface or subsurface
strata), including laws relating to emissions, discharges, releases
or threatened releases of chemicals, pollutants, contaminants, or
toxic or hazardous substances or wastes (collectively,
“Hazardous
Materials”) into the environment, or otherwise
relating to the manufacture, processing, distribution, use,
treatment, storage, disposal, transport or handling of Hazardous
Materials, as well as all authorizations, codes, decrees, demands,
or demand letters, injunctions, judgments, licenses, notices or
notice letters, orders, permits, plans or regulations, issued,
entered, promulgated or approved thereunder (“Environmental Laws”);
(ii) have received all permits licenses or other approvals required
of them under applicable Environmental Laws to conduct their
respective businesses; and (iii) are in compliance with all terms
and conditions of any such permit, license or approval where in
each clause (i), (ii) and (iii), the failure to so comply could be
reasonably expected to have, individually or in the aggregate, a
Material Adverse Effect.
ARTICLE
IV.
OTHER
AGREEMENTS OF THE PARTIES
4.1 Amendments to Registration
Statement. The Company has delivered, or will as promptly as
practicable deliver, to the Underwriters complete conformed copies
of the Registration Statement and of each consent and certificate
of experts, as applicable, filed as a part thereof, and conformed
copies of the Registration Statement (without exhibits), the
Prospectus and the Prospectus Supplement, as amended or
supplemented in such quantities and at such places as an
Underwriter reasonably requests. Neither the Company nor any of its
directors and officers has distributed and none of them will
distribute, prior to the Closing Date, any offering material in
connection with the offering and sale of the Public Shares other
than the Prospectus, the Prospectus Supplement, the Registration
Statement, and copies of the documents incorporated by reference
therein. The Company shall not file any such amendment or
supplement to which the Representative shall reasonably object in
writing.
24
4.2 Federal Securities
Laws.
(a) Compliance. During the time
when a Prospectus is required to be delivered under the Securities
Act, the Company will use its best efforts to comply with all
requirements imposed upon it by the Securities Act and the rules
and regulations thereunder and the Exchange Act and the rules and
regulations thereunder, as from time to time in force, so far as
necessary to permit the continuance of sales of or dealings in the
Public Shares in accordance with the provisions hereof and the
Prospectus. If at any time when a Prospectus relating to the Public
Shares is required to be delivered under the Securities Act, any
event shall have occurred as a result of which, in the opinion of
counsel for the Company or counsel for the Underwriters, the
Prospectus, as then amended or supplemented, includes an untrue
statement of a material fact or omits to state any material fact
required to be stated therein or necessary to make the statements
therein, in light of the circumstances under which they were made,
not misleading, or if it is necessary at any time to amend the
Prospectus to comply with the Securities Act, the Company will
notify the Underwriters promptly and prepare and file with the
Commission, subject to Section 4.1 hereof, an appropriate amendment
or supplement in accordance with Section 10 of the Securities
Act.
(b) Filing of Final Prospectus
Supplement. The Company will file the Prospectus Supplement
(in form and substance reasonably satisfactory to the
Representative) with the Commission pursuant to the requirements of
Rule 424.
(c) Exchange Act Registration. For
a period of three (3) years from the Execution Date, the Company
will use its best efforts to maintain the registration of the
Common Stock under the Exchange Act. The Company will not
deregister the Common Stock under the Exchange Act without the
prior written consent of the Representative.
(d) Free Writing Prospectuses. The
Company represents and agrees that it has not made and will not
make any offer relating to the Public Shares that would constitute
an issuer free writing prospectus, as defined in Rule 433 of the
rules and regulations under the Securities Act, without the prior
written consent of the Representative. Any such free writing
prospectus consented to by the Representative is herein referred to
as a “Permitted Free Writing
Prospectus.” The Company represents that it will treat
each Permitted Free Writing Prospectus as an “issuer free
writing prospectus” as defined in rules and regulations under
the Securities Act, and has complied and will comply with the
applicable requirements of Rule 433 of the Securities Act,
including timely Commission filing where required, legending and
record keeping.
4.3 Delivery to the Underwriters of
Prospectuses. The Company will deliver to the Underwriters,
without charge, from time to time during the period when the
Prospectus is required to be delivered under the Securities Act or
the Exchange Act such number of copies of each Prospectus as the
Underwriters may reasonably request and, as soon as the
Registration Statement or any amendment or supplement thereto
becomes effective, deliver to you two original executed
Registration Statements, including exhibits, and all post-effective
amendments thereto and copies of all exhibits filed therewith or
incorporated therein by reference and all original executed
consents of certified experts.
25
4.4 Effectiveness and Events Requiring
Notice to the Underwriters. The Company will use its best
efforts to cause the Registration Statement to remain effective
with a current prospectus until nine (9) months from the Execution
Date, and will notify the Underwriters immediately and confirm the
notice in writing: (i) of the effectiveness of the Registration
Statement and any amendment thereto; (ii) of the issuance by the
Commission of any stop order or of the initiation, or the
threatening, of any proceeding for that purpose; (iii) of the
issuance by any state securities commission of any proceedings for
the suspension of the qualification of the Public Shares for
offering or sale in any jurisdiction or of the initiation, or the
threatening, of any proceeding for that purpose; (iv) of the
mailing and delivery to the Commission for filing of any amendment
or supplement to the Registration Statement or Prospectus; (v) of
the receipt of any comments or request for any additional
information from the Commission; and (vi) of the happening of any
event during the period described in this Section 4.4 that, in the
judgment of the Company, makes any statement of a material fact
made in the Registration Statement or the Prospectus untrue or that
requires the making of any changes in the Registration Statement or
the Prospectus in order to make the statements therein, in light of
the circumstances under which they were made, not misleading. If
the Commission or any state securities commission shall enter a
stop order or suspend such qualification at any time, the Company
will make every reasonable effort to obtain promptly the lifting of
such order.
4.5 Review of Financial Statements.
For a period of five (5) years from the Execution Date, the
Company, at its expense, shall cause its regularly engaged
independent registered public accountants to review (but not audit)
the Company’s financial statements for each of the first
three fiscal quarters prior to the announcement of quarterly
financial information.
4.6
Reports to the
Underwriters; Expenses of the Offering.
(a) Periodic Reports, etc. For a
period of three years from the Execution Date, the Company will
furnish to the Underwriters copies of such financial statements and
other periodic and special reports as the Company from time to time
furnishes generally to holders of any class of its securities and
also promptly furnish to the Underwriters: (i) a copy of each
periodic report the Company shall be required to file with the
Commission; (ii) a copy of every press release and every news item
and article with respect to the Company or its affairs which was
released by the Company; (iii) a copy of each Form 8-K prepared and
filed by the Company; (iv) a copy of each registration statement
filed by the Company under the Securities Act; (v) such additional
documents and information with respect to the Company and the
affairs of any future Subsidiaries of the Company as the
Representative may from time to time reasonably request; provided
that the Underwriters shall each sign, if requested by the Company,
a Regulation FD compliant confidentiality agreement which is
reasonably acceptable to the Representative in connection with such
Underwriter’s receipt of such information. Documents filed
with the Commission pursuant to its XXXXX system shall be deemed to
have been delivered to the Underwriters pursuant to this
Section.
(b)
[Intentionally
Omitted].
(c)
[Intentionally
Omitted].
26
(d) General Expenses Related to the
Offering. The Company hereby agrees to pay on each of the
Closing Date and each Option Closing Date, if any, to the extent
not paid at the Closing Date, all expenses incident to the
performance of the obligations of the Company under this Agreement,
including, but not limited to: (a) all filing fees and
communication expenses relating to the registration of the Public
Shares to be sold in the Offering (including the Option Shares)
with the Commission; (b) all fees and expenses relating to the
listing of such Closing Shares and Option Shares on the Trading
Market and such other stock exchanges as the Company and the
Representative together determine; (d) all actual and reasonable
fees, expenses and disbursements relating to the registration or
qualification of such Public Shares under the “blue
sky” securities laws of such states and other foreign
jurisdictions as the Representative may reasonably designate
(including, without limitation, all filing and registration fees,
and the fees and expenses of Blue Sky counsel) unless such filings
are not required in connection with the Company’s proposed
listing on a national exchange, if applicable; (e) the costs of all
mailing and printing of the underwriting documents (including,
without limitation, the Underwriting Agreement, any Blue Sky
Surveys and, if appropriate, any Agreement Among Underwriters,
Selected Dealers’ Agreement, Underwriters’
Questionnaire and Power of Attorney), Registration Statements,
Prospectuses and all amendments, supplements and exhibits thereto
and as many preliminary and final Prospectuses as the
Representative may reasonably deem necessary; (f) stock transfer
and/or stamp taxes, if any, payable upon the transfer of securities
from the Company to the Underwriters; (g) the fees and
expenses of the Company’s accountants; and (h) a maximum of
$50,000 for fees and expenses (the “Expense Cap”) including
“road show”, diligence and reasonable legal fees and
disbursements for Underwriters’ counsel. Additionally, the
Representative shall be entitled to a non-accountable expense
allowance equal to one percent (1.0%) of the gross proceeds in this
offering. Such non-accountable expense allowance shall not be
deemed included in the Expense Cap. In the event the Offering is
not consummated, a maximum of $20,000 will be payable by the
Company for such expenses. The Underwriters may also deduct from
the net proceeds of the Offering payable to the Company on the
Closing Date, or each Option Closing Date, if any, the expenses set
forth herein to be paid by the Company to the
Underwriters.
4.7 Application of Net Proceeds.
The Company will apply the net proceeds from the Offering received
by it in a manner consistent with the application described under
the caption “Use of Proceeds” in the
Prospectus.
4.8
[Intentionally
Omitted].
4.9 Stabilization. Neither the
Company, nor, to its knowledge, any of its employees, directors or
shareholders (without the consent of the Representative) has taken
or will take, directly or indirectly, any action designed to or
that has constituted or that might reasonably be expected to cause
or result in, under the Exchange Act, or otherwise, stabilization
or manipulation of the price of any security of the Company to
facilitate the sale or resale of the Public Shares.
4.10 Internal
Controls. The Company will maintain a system of internal
accounting controls sufficient to provide reasonable assurances
that: (i) transactions are executed in accordance with
management’s general or specific authorization; (ii)
transactions are recorded as necessary in order to permit
preparation of financial statements in accordance with GAAP and
to
27
maintain
accountability for assets; (iii) access to assets is permitted only
in accordance with management’s general or specific
authorization; and (iv) the recorded accountability for assets is
compared with existing assets at reasonable intervals and
appropriate action is taken with respect to any
differences.
4.11 Accountants.
The Company shall continue to retain a nationally recognized
independent certified public accounting firm for a period of at
least three years after the Execution Date. The Underwriters
acknowledge that the Company Auditor is acceptable to the
Underwriters.
4.12 FINRA.
For a period of 12 months after the Execution Date, the Company
shall advise the Underwriters (who shall make an appropriate filing
with FINRA) if it is aware that any 10% or greater shareholder of
the Company becomes an affiliate or associated person of an
Underwriter.
4.13 No
Fiduciary Duties. The Company acknowledges and agrees that
the Underwriters’ responsibility to the Company is solely
contractual and commercial in nature, based on arms-length
negotiations and that neither the Underwriters nor their affiliates
or any selected dealer shall be deemed to be acting in a fiduciary
capacity, or otherwise owes any fiduciary duty to the Company or
any of its affiliates in connection with the Offering and the other
transactions contemplated by this Agreement. Notwithstanding
anything in this Agreement to the contrary, the Company
acknowledges that the Underwriters may have financial interests in
the success of the Offering that are not limited to the difference
between the price to the public and the purchase price paid to the
Company by the Underwriters for the shares and the Underwriters
have no obligation to disclose, or account to the Company for, any
of such additional financial interests. The Company hereby waives
and releases, to the fullest extent permitted by law, any claims
that the Company may have against the Underwriters with respect to
any breach or alleged breach of fiduciary duty.
4.14
[Intentionally
Omitted].
4.15
Board Composition and Board
Designations. The Company shall ensure that:
(i) the
qualifications of the persons serving as board members and the
overall composition of the Board of Directors comply with the
Xxxxxxxx-Xxxxx Act of 2002 and the rules promulgated thereunder and
with the listing requirements of the Trading Market (subject to
applicable cure periods provided thereby) and (ii) if applicable,
at least one member of the Board of Directors qualifies as a
“financial expert” as such term is defined under the
Xxxxxxxx-Xxxxx Act of 2002 and the rules promulgated
thereunder.
4.16
Securities Laws
Disclosure; Publicity. At the request of the Representative,
by 9:00 a.m. (New York City
time) on the date hereof, the Company shall issue a press release
disclosing the material terms of the Offering. The Company and the
Representative shall consult with each other in issuing any other
press releases with respect to the Offering, and neither the
Company nor any Underwriter shall issue any such press release nor
otherwise make any such public statement without the prior consent
of the Company, with respect to any press release of such
Underwriter, or without the prior consent of such Underwriter, with
respect to any press release of the Company, which consent shall
not unreasonably be withheld or delayed, except if such disclosure
is required
28
by law,
in which case the disclosing party shall promptly provide the other
party with prior notice of such public statement or communication.
The Company will not issue press releases or engage in any other
publicity, without the Representative’s prior written
consent, for a period ending at 5:00 p.m. (New York City time) on
the first business day following the 45th day following the Closing
Date, other than normal and customary releases issued in the
ordinary course of the Company’s business.
4.17 Shareholder
Rights Plan. No claim will be made or enforced by the
Company or, with the consent of the Company, any other Person, that
any Underwriter of the Public Shares is an “Acquiring
Person” under any control share acquisition, business
combination, poison pill (including any distribution under a rights
agreement) or similar anti-takeover plan or arrangement in effect
or hereafter adopted by the Company, or that any Underwriter of
Public Shares could be deemed to trigger the provisions of any such
plan or arrangement, by virtue of receiving Public
Shares.
4.18 Reservation
of Common Stock. As of the date hereof, the Company has
reserved and the Company shall continue to reserve and keep
available at all times, free of preemptive rights, a sufficient
number of shares of Common Stock for the purpose of enabling the
Company to issue Option Shares pursuant to the Over-Allotment
Option.
4.19 Listing
of Common Stock. The Company hereby agrees to use best
efforts to maintain the listing or quotation of the Common Stock on
the Trading Market on which it is currently listed, and
concurrently with the Closing, the Company shall apply to list or
quote all of the Closing Shares and Option Shares on such Trading
Market and promptly secure the listing of all of the Closing
Shares, Option Shares on such Trading Market. The Company further
agrees, if the Company applies to have the Common Stock traded on
any other Trading Market, it will then include in such application
all of the Closing Shares and Option Shares, and will take such
other action as is necessary to cause all of the Closing Shares and
Option Shares, to be listed or quoted on such other Trading Market
as promptly as possible. The Company will then take all action
reasonably necessary to continue the listing and trading of its
Common Stock on a Trading Market and will comply in all respects
with the Company’s reporting, filing and other obligations
under the bylaws or rules of the Trading Market. The Company agrees
to maintain the eligibility of the Common Stock for electronic
transfer through the Depository Trust Company or another
established clearing corporation, including, without limitation, by
timely payment of fees to the Depository Trust Company or such
other established clearing corporation in connection with such
electronic transfer.
4.20
[Intentionally
Omitted].
4.21
Subsequent Equity
Sales.
(a) The Company, on
behalf of itself and any successor entity, agrees that, without the
prior written consent of the Representative, it will not, for a
period of forty five (45) days after the date of this Agreement
(the “Lock-Up
Period”), (i) offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or
contract to sell, grant any option, right or warrant to purchase,
lend, or otherwise transfer or dispose of, directly or
indirectly,
29
any
shares of capital stock of the Company or any securities
convertible into or exercisable or exchangeable for shares of
capital stock of the Company; (ii) file or caused to be filed any
registration statement with the Commission relating to the offering
of any shares of capital stock of the Company or any securities
convertible into or exercisable or exchangeable for shares of
capital stock of the Company; (iii) complete any offering of debt
securities of the Company, other than entering into a line of
credit with a traditional bank or (iv) enter into any swap or other
arrangement that transfers to another, in whole or in part, any of
the economic consequences of ownership of capital stock of the
Company, whether any such transaction described in clause (i),
(ii), (iii) or (iv) above is to be settled by delivery of shares of
capital stock of the Company or such other securities, in cash or
otherwise.
(b) From the date
hereof until ninety (90) days from the Closing Date, the Company
shall be prohibited from effecting or entering into an
agreement to effect any issuance by the Company or any of its
Subsidiaries of Common Stock or Common Stock Equivalents (or a
combination of units thereof) involving a Variable Rate
Transaction. “Variable Rate
Transaction” means a transaction in which the Company
(i) issues or sells any debt or equity securities that are
convertible into, exchangeable or exercisable for, or include the
right to receive, additional shares of Common Stock either (A) at a
conversion price, exercise price or exchange rate or other price
that is based upon, and/or varies with, the trading prices of or
quotations for the shares of Common Stock at any time after the
initial issuance of such debt or equity securities or (B) with a
conversion, exercise or exchange price that is subject to being
reset at some future date after the initial issuance of such debt
or equity security or upon the occurrence of specified or
contingent events directly or indirectly related to the business of
the Company or the market for the Common Stock or (ii) enters into,
or effects a transaction under, any agreement, including, but not
limited to, an equity line of credit, whereby the Company may issue
securities at a future determined price. Any Underwriter shall be
entitled to obtain injunctive relief against the Company to
preclude any such issuance, which remedy shall be in addition to
any right to collect damages.
(c) Notwithstanding the
foregoing, this Section 4.21 shall not apply in respect of an
Exempt Issuance, except that no Variable Rate Transaction shall be
an Exempt Issuance.
4.22 Capital
Changes. Until the one (1) year anniversary of the Closing
Date, the Company shall not undertake a reverse or forward stock
split or reclassification of the Common Stock without the prior
written consent of the Representative, which shall not be
unreasonably withheld, conditioned or delayed. Notwithstanding the
foregoing, no consent shall be required in the event a reverse
stock split is deemed reasonably necessary by the Board of
Directors of the Company in order for the Company to comply with
the initial listing requirements of The NASDAQ Capital Market
following the closing of the transactions contemplated by the
HotPlay Agreement.
4.23
[Intentionally
Omitted].
4.24
[Intentionally
Omitted].
4.25 Research
Independence. The Company acknowledges that each
Underwriter’s research analysts and research departments, if
any, are required to be independent from their
30
respective
investment banking divisions and are subject to certain regulations
and internal policies, and that such Underwriter’s research
analysts may hold and make statements or investment recommendations
and/or publish research reports with respect to the Company and/or
the offering that differ from the views of its investment bankers.
The Company hereby waives and releases, to the fullest extent
permitted by law, any claims that the Company may have against such
Underwriter with respect to any conflict of interest that may arise
from the fact that the views expressed by their independent
research analysts and research departments may be different from or
inconsistent with the views or advice communicated to the Company
by such Underwriter’s investment banking divisions. The
Company acknowledges that each of the Representative is a full
service securities firm and as such from time to time, subject to
applicable securities laws, may effect transactions for its own
account or the account of their respective customers and hold long
or short position in debt or equity securities of the
Company.
ARTICLE
V.
DEFAULT
BY UNDERWRITERS
If on
the Closing Date or any Option Closing Date, if any, any
Underwriter shall fail to purchase and pay for the portion of the
Closing Shares or Option Shares, as the case may be, which such
Underwriter has agreed to purchase and pay for on such date
(otherwise than by reason of any default on the part of the
Company), the Representative, or if the Representative is the
defaulting Underwriter, the non-defaulting Underwriters, shall use
their reasonable efforts to procure within 36 hours thereafter one
or more of the other Underwriters, or any others, to purchase from
the Company such amounts as may be agreed upon and upon the terms
set forth herein, the Closing Shares or Option Shares, as the case
may be, which the defaulting Underwriter or Underwriters failed to
purchase. If during such 36 hours the Representative shall not have
procured such other Underwriters, or any others, to purchase the
Closing Shares or Option Shares, as the case may be, agreed to be
purchased by the defaulting Underwriter or Underwriters, then (a)
if the aggregate number of Closing Shares or Option Shares, as the
case may be, with respect to which such default shall occur does
not exceed 10% of the Closing Shares or Option Shares, as the case
may be, covered hereby, the other Underwriters shall be obligated,
severally, in proportion to the respective numbers of Closing
Shares or Option Shares, as the case may be, which they are
obligated to purchase hereunder, to purchase the Closing Shares or
Option Shares, as the case may be, which such defaulting
Underwriter or Underwriters failed to purchase, or (b) if the
aggregate number of Closing Shares or Option Shares, as the case
may be, with respect to which such default shall occur exceeds 10%
of the Closing Shares or Option Shares, as the case may be, covered
hereby, the Company or the Representative will have the right to
terminate this Agreement without liability on the part of the
non-defaulting Underwriters or of the Company except to the extent
provided in Article VI hereof. In the event of a default by any
Underwriter or Underwriters, as set forth in this Article V, the
applicable Closing Date may be postponed for such period, not
exceeding seven (7) days, as the Representative, or if the
Representative is the defaulting Underwriter, the non-defaulting
Underwriters, may determine in order that the required changes in
the Prospectus or in any other documents or arrangements may be
effected. The term “Underwriter” includes any person
substituted for a defaulting Underwriter. Any action taken under
this Section shall not relieve any defaulting Underwriter from
liability in respect of any default of such Underwriter under this
Agreement.
31
ARTICLE
VI.
INDEMNIFICATION
6.1 Indemnification
of the Underwriters. Subject to the conditions set forth
below, the Company agrees to indemnify and hold harmless the
Underwriters, and each dealer selected by each Underwriter that
participates in the offer and sale of the Public Shares (each a
“Selected
Dealer”) and
each of their respective directors, officers and employees and each
Person, if any, who controls such Underwriter or any Selected
Dealer (“Controlling
Person”) within the meaning of Section 15 of the
Securities Act or Section 20 of the Exchange Act, against any and
all loss, liability, claim, damage and expense whatsoever
(including but not limited to any and all legal or other expenses
reasonably incurred in investigating, preparing or defending
against any litigation, commenced or threatened, or any claim
whatsoever, whether arising out of any action between such
Underwriter and the Company or between such Underwriter and any
third party or otherwise) to which they or any of them may become
subject under the Securities Act, the Exchange Act or any other
statute or at common law or otherwise or under the laws of foreign
countries, arising out of or based upon any untrue statement or
alleged untrue statement of a material fact contained in(i) any
Preliminary Prospectus, if any, the Registration Statement or the
Prospectus (as from time to time each may be amended and
supplemented); (ii) any materials or information provided to
investors by, or with the approval of, the Company in connection
with the marketing of the offering of the Public Shares, including
any “road show” or investor presentations made to
investors by the Company (whether in person or electronically); or
(iii) any application or other document or written communication
(in this Article VI, collectively called “application”) executed by
the Company or based upon written information furnished by the
Company in any jurisdiction in order to qualify the Public Shares
under the securities laws thereof or filed with the Commission, any
state securities commission or agency, Trading Market or any
securities exchange; or the omission or alleged omission therefrom
of a material fact required to be stated therein or necessary to
make the statements therein, in light of the circumstances under
which they were made, not misleading, unless such statement or
omission was made in reliance upon and in conformity with written
information furnished to the Company with respect to the applicable
Underwriter by or on behalf of such Underwriter expressly for use
in any Preliminary Prospectus, if any, the Registration Statement
or Prospectus, or any amendment or supplement thereto, or in any
application, as the case may be. With respect to any untrue
statement or omission or alleged untrue statement or omission made
in the Preliminary Prospectus, if any, the indemnity agreement
contained in this Section 6.1 shall not inure to the benefit of an
Underwriter to the extent that any loss, liability, claim, damage
or expense of such Underwriter results from the fact that a copy of
the Prospectus was not given or sent to the Person asserting any
such loss, liability, claim or damage at or prior to the written
confirmation of sale of the Public Shares to such Person as
required by the Securities Act and the rules and regulations
thereunder, and if the untrue statement or omission has been
corrected in the Prospectus, unless such failure to deliver the
Prospectus was a result of non- compliance by the Company with its
obligations under this Agreement. The Company agrees promptly to
notify each Underwriter of the commencement of any litigation or
proceedings against the Company or any of its officers, directors
or Controlling Persons in connection with the issue and sale of the
Public Shares or in connection with the Registration Statement or
Prospectus.
32
6.2 Procedure. If any action is
brought against an Underwriter, a Selected Dealer or a Controlling
Person in respect of which indemnity may be sought against the
Company pursuant to Section 6.1, such Underwriter, such Selected
Dealer or Controlling Person, as the case may be, shall promptly
notify the Company in writing of the institution of such action and
the Company shall assume the defense of such action, including the
employment and fees of counsel (subject to the reasonable approval
of such Underwriter or such Selected Dealer, as the case may be)
and payment of actual expenses. Such Underwriter, such Selected
Dealer or Controlling Person shall have the right to employ its or
their own counsel in any such case, but the fees and expenses of
such counsel shall be at the expense of such Underwriter, such
Selected Dealer or Controlling Person unless (i) the employment of
such counsel at the expense of the Company shall have been
authorized in writing by the Company in connection with the defense
of such action, or (ii) the Company shall not have employed counsel
to have charge of the defense of such action, or (iii) such
indemnified party or parties shall have reasonably concluded that
there may be defenses available to it or them which are different
from or additional to those available to the Company (in which case
the Company shall not have the right to direct the defense of such
action on behalf of the indemnified party or parties), in any of
which events the reasonable fees and expenses of not more than one
additional firm of attorneys selected by such Underwriter (in
addition to local counsel), Selected Dealer and/or Controlling
Person shall be borne by the Company. Notwithstanding anything to
the contrary contained herein, if any Underwriter, Selected Dealer
or Controlling Person shall assume the defense of such action as
provided above, the Company shall have the right to approve the
terms of any settlement of such action which approval shall not be
unreasonably withheld.
6.3 Indemnification of the Company.
Each Underwriter severally and not jointly agrees to indemnify and
hold harmless the Company, its directors, officers and employees
and agents who control the Company within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act against any
and all loss, liability, claim, damage and expense described in the
foregoing indemnity from the Company to such Underwriter, as
incurred, but only with respect to untrue statements or omissions,
or alleged untrue statements or omissions made in any Preliminary
Prospectus, if any, the Registration Statement or Prospectus or any
amendment or supplement thereto or in any application, in reliance
upon, and in strict conformity with, written information furnished
to the Company with respect to such Underwriter by or on behalf of
such Underwriter expressly for use in such Preliminary Prospectus,
if any, the Registration Statement or Prospectus or any amendment
or supplement thereto or in any such application. In case any
action shall be brought against the Company or any other Person so
indemnified based on any Preliminary Prospectus, if any, the
Registration Statement or Prospectus or any amendment or supplement
thereto or any application, and in respect of which indemnity may
be sought against such Underwriter, such Underwriter shall have the
rights and duties given to the Company, and the Company and each
other Person so indemnified shall have the rights and duties given
to such Underwriter by the provisions of this Article VI.
Notwithstanding the provisions of this Section 6.3, no Underwriter
shall be required to indemnify the Company for any amount in excess
of the underwriting discounts and commissions applicable to the
Public Shares purchased by such Underwriter. The Underwriters'
obligations in this Section 6.3 to indemnify the Company are
several in proportion to their respective underwriting obligations
and not joint.
33
6.4
Contribution.
(a) Contribution Rights. In order
to provide for just and equitable contribution under the Securities
Act in any case in which (i) any Person entitled to indemnification
under this Article VI makes a claim for indemnification pursuant
hereto but it is judicially determined (by the entry of a final
judgment or decree by a court of competent jurisdiction and the
expiration of time to appeal or the denial of the last right of
appeal) that such indemnification may not be enforced in such case
notwithstanding the fact that this Article VI provides for
indemnification in such case, or (ii) contribution under the
Securities Act, the Exchange Act or otherwise may be required on
the part of any such Person in circumstances for which
indemnification is provided under this Article VI, then, and in
each such case, the Company and each Underwriter, severally and not
jointly, shall contribute to the aggregate losses, liabilities,
claims, damages and expenses of the nature contemplated by said
indemnity agreement incurred by the Company and such Underwriter,
as incurred, in such proportions that such Underwriter is
responsible for that portion represented by the percentage that the
underwriting discount appearing on the cover page of the Prospectus
bears to the initial offering price appearing thereon and the
Company is responsible for the balance; provided, that, no Person
guilty of a fraudulent misrepresentation (within the meaning of
Section 11(f) of the Securities Act) shall be entitled to
contribution from any Person who was not guilty of such fraudulent
misrepresentation. For purposes of this Section, each director,
officer and employee of such Underwriter or the Company, as
applicable, and each Person, if any, who controls such Underwriter
or the Company, as applicable, within the meaning of Section 15 of
the Securities Act shall have the same rights to contribution as
such Underwriter or the Company, as applicable. Notwithstanding the
provisions of this Section 6.4, no Underwriter shall be required to
contribute any amount in excess of the underwriting discounts and
commissions applicable to the Public Shares purchased by such
Underwriter. The Underwriters' obligations in this Section 6.4 to
contribute are several in proportion to their respective
underwriting obligations and not joint.
(b) Contribution Procedure. Within
fifteen days after receipt by any party to this Agreement (or its
representative) of notice of the commencement of any action, suit
or proceeding, such party will, if a claim for contribution in
respect thereof is to be made against another party
(“contributing
party”), notify the contributing party of the
commencement thereof, but the failure to so notify the contributing
party will not relieve it from any liability which it may have to
any other party other than for contribution hereunder. In case any
such action, suit or proceeding is brought against any party, and
such party notifies a contributing party or its representative of
the commencement thereof within the aforesaid fifteen days, the
contributing party will be entitled to participate therein with the
notifying party and any other contributing party similarly
notified. Any such contributing party shall not be liable to any
party seeking contribution on account of any settlement of any
claim, action or proceeding affected by such party seeking
contribution without the written consent of such contributing
party. The contribution provisions contained in this Section 6.4
are intended to supersede, to the extent permitted by law, any
right to contribution under the Securities Act, the Exchange Act or
otherwise available.
34
ARTICLE
VII.
MISCELLANEOUS
7.1
Termination.
(a) Termination Right. The
Representative shall have the right to terminate this Agreement at
any time prior to any Closing Date, (i) if any domestic or
international event or act or occurrence has materially disrupted,
or in its opinion will in the immediate future materially disrupt,
general securities markets in the United States; or (ii) if trading
on any Trading Market shall have been suspended or materially
limited, or minimum or maximum prices for trading shall have been
fixed, or maximum ranges for prices for securities shall have been
required by FINRA or by order of the Commission or any other
government authority having jurisdiction, or (iii) if the United
States shall have become involved in a new war or an increase in
major hostilities, or (iv) if a banking moratorium has been
declared by a New York State or federal authority, or (v) if a
moratorium on foreign exchange trading has been declared which
materially adversely impacts the United States securities markets,
or (vi) if the Company shall have sustained a material loss by
fire, flood, accident, hurricane, earthquake, theft, sabotage or
other calamity or malicious act which, whether or not such loss
shall have been insured, will, in the Representative’s
opinion, make it inadvisable to proceed with the delivery of the
Public Shares, or (vii) if the Company is in material breach of any
of its representations, warranties or covenants hereunder, or
(viii) if the Representative shall have become aware after the date
hereof of such a material adverse change in the conditions or
prospects of the Company, or such adverse material change in
general market conditions as in the Representative’s judgment
would make it impracticable to proceed with the offering, sale
and/or delivery of the Public Shares or to enforce contracts made
by the Underwriters for the sale of the Public Shares.
(b) Expenses. In the event this
Agreement shall be terminated pursuant to Section 7.1(a), within
the time specified herein or any extensions thereof pursuant to the
terms herein, the Company shall be obligated to pay to the
Representative their actual and accountable out of pocket expenses
related to the transactions contemplated herein then due and
payable, subject to the cap on such fees set forth in Section
4.6(d).
(c) Indemnification.
Notwithstanding any contrary provision contained in this Agreement,
any election hereunder or any termination of this Agreement, and
whether or not this Agreement is otherwise carried out, the
provisions of Article VI shall not be in any way effected by such
election or termination or failure to carry out the terms of this
Agreement or any part hereof.
7.2 Entire Agreement. The
Transaction Documents, together with the exhibits and schedules
thereto, the Prospectus and the Prospectus Supplement, contain the
entire understanding of the parties with respect to the subject
matter hereof and thereof and supersede all prior agreements and
understandings, oral or written, with respect to such matters,
which the parties acknowledge have been merged into such documents,
exhibits and schedules. Notwithstanding anything herein to the
contrary, the Engagement Agreement, dated May 13, 2021
(“Engagement
Agreement”),
by and between the Company and the Representative, shall continue
to be effective and the terms therein shall continue to survive and
be enforceable by the Representative in
35
accordance with its
terms, provided that, in the event of a conflict between the terms
of the Engagement Agreement and this Agreement, the terms of this
Agreement shall prevail.
7.3 Notices. Any and all notices or
other communications or deliveries required or permitted to be
provided hereunder shall be in writing and shall be deemed given
and effective on the earliest of: (a) the date of transmission, if
such notice or communication is delivered via facsimile at the
facsimile number or e-mail attachment at the email address set
forth on the signature pages attached hereto at or prior to 5:30
p.m. (New York City time) on a Trading Day, (b) the next
Trading Day after the date of transmission, if such notice or
communication is delivered via facsimile at the facsimile number or
e-mail attachment at the e-mail address as set forth on the
signature pages attached hereto on a day that is not a Trading Day
or later than 5:30p.m. (New York City time) on any Trading Day, (c)
the second (2nd) Trading Day
following the date of mailing, if sent by U.S. nationally
recognized overnight courier service or (d) upon actual receipt by
the party to whom such notice is required to be given. The address
for such notices and communications shall be as set forth on the
signature pages attached hereto.
7.4 Amendments; Waivers. No
provision of this Agreement may be waived, modified, supplemented
or amended except in a written instrument signed, in the case of an
amendment, by the Company and the Representative. No waiver of any
default with respect to any provision, condition or requirement of
this Agreement shall be deemed to be a continuing waiver in the
future or a waiver of any subsequent default or a waiver of any
other provision, condition or requirement hereof, nor shall any
delay or omission of any party to exercise any right hereunder in
any manner impair the exercise of any such right.
7.5 Headings. The headings herein
are for convenience only, do not constitute a part of this
Agreement and shall not be deemed to limit or affect any of the
provisions hereof.
7.6 Successors and Assigns. This
Agreement shall be binding upon and inure to the benefit of the
parties and their successors and permitted assigns.
7.7 Governing Law. All questions
concerning the construction, validity, enforcement and
interpretation of the Transaction Documents shall be governed by
and construed and enforced in accordance with the internal laws of
the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all legal
proceedings concerning the interpretations, enforcement and defense
of the transactions contemplated by this Agreement and any other
Transaction Documents (whether brought against a party hereto or
its respective affiliates, directors, officers, shareholders,
partners, members, employees or agents) shall be commenced
exclusively in the state and federal courts sitting in the City of
New York. Each party hereby irrevocably submits to the exclusive
jurisdiction of the state and federal courts sitting in the City of
New York, Borough of Manhattan for the adjudication of any dispute
hereunder or in connection herewith or with any transaction
contemplated hereby or discussed herein (including with respect to
the enforcement of any of the Transaction Documents), and hereby
irrevocably waives, and agrees not to assert in any action, suit or
proceeding, any claim that it is not personally subject to the
jurisdiction of any such court, that such suit, action or
proceeding is improper or is an inconvenient venue for such
proceeding. Each party hereby irrevocably waives personal service
of process and consents to process being served in any such suit,
action or proceeding by mailing
36
a copy
thereof via registered or certified mail or overnight delivery
(with evidence of delivery) to such party at the address in effect
for notices to it under this Agreement and agrees that such service
shall constitute good and sufficient service of process and notice
thereof. Nothing contained herein shall be deemed to limit in any
way any right to serve process in any other manner permitted by
law. If either party shall commence an action or proceeding to
enforce any provisions of the Transaction Documents, then, in
addition to the obligations of the Company under Article VI, the
prevailing party in such action, suit or proceeding shall be
reimbursed by the other party for its reasonable attorneys’
fees and other costs and expenses incurred with the investigation,
preparation and prosecution of such action or
proceeding.
7.8 Survival. The representations
and warranties contained herein shall survive the Closing and the
Option Closing, if any, and the delivery of the Public
Shares.
7.9 Execution. This Agreement may
be executed in two or more counterparts, all of which when taken
together shall be considered one and the same agreement and shall
become effective when counterparts have been signed by each party
and delivered to each other party, it being understood that the
parties need not sign the same counterpart. In the event that any
signature is delivered by facsimile transmission or by e-mail
delivery of a “.pdf” format data file, such signature
shall create a valid and binding obligation of the party executing
(or on whose behalf such signature is executed) with the same force
and effect as if such facsimile or “.pdf” signature
page were an original thereof.
7.10 Severability.
If any term, provision, covenant or restriction of this Agreement
is held by a court of competent jurisdiction to be invalid,
illegal, void or unenforceable, the remainder of the terms,
provisions, covenants and restrictions set forth herein shall
remain in full force and effect and shall in no way be affected,
impaired or invalidated, and the parties hereto shall use their
commercially reasonable efforts to find and employ an alternative
means to achieve the same or substantially the same result as that
contemplated by such term, provision, covenant or restriction. It
is hereby stipulated and declared to be the intention of the
parties that they would have executed the remaining terms,
provisions, covenants and restrictions without including any of
such that may be hereafter declared invalid, illegal, void or
unenforceable.
7.11 Remedies.
In addition to being entitled to exercise all rights provided
herein or granted by law, including recovery of damages, the
Underwriters and the Company will be entitled to specific
performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss
incurred by reason of any breach of obligations contained in the
Transaction Documents and hereby agree to waive and not to assert
in any action for specific performance of any such obligation the
defense that a remedy at law would be adequate.
7.12 Saturdays,
Sundays, Holidays, etc. If the last or appointed day for the
taking of any action or the expiration of any right required or
granted herein shall not be a Business Day, then such action may be
taken or such right may be exercised on the next succeeding
Business Day.
37
7.13 Construction.
The parties agree that each of them and/or their respective counsel
have reviewed and had an opportunity to revise the Transaction
Documents and, therefore, the normal rule of construction to the
effect that any ambiguities are to be resolved against the drafting
party shall not be employed in the interpretation of the
Transaction Documents or any amendments thereto. In addition, each
and every reference to share prices and shares of Common Stock in
any Transaction Document shall be subject to adjustment for reverse
and forward stock splits, stock dividends, stock combinations and
other similar transactions of the Common Stock that occur after the
date of this Agreement.
7.14 WAIVER
OF JURY TRIAL. IN ANY ACTION, SUIT, OR PROCEEDING IN ANY
JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY ARISING
OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS
CONTEMPLATED HEREBY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY,
TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY
ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND EXPRESSLY WAIVE
FOREVER ANY RIGHT TO TRIAL BY JURY.
(Signature Pages Follow)
38
If the
foregoing correctly sets forth the understanding between the
Underwriters and the Company, please so indicate in the space
provided below for that purpose, whereupon this letter shall
constitute a binding agreement among the Company and the several
Underwriters in accordance with its terms.
Address
for Notice: 0000 Xxxxxxxx Xxxxxxxxx Xxxxxxx
Xxxxx
000
Xxxxxxx
Xxxxxxx 00000
Copy
to:
[Signature Page Continues on Next
Page]
39
Accepted on the
date first above written.
KINGSWOOD
CAPITAL MARKETS, division of
BENCHMARK
INVESTMENTS, INC.
As a
Representative of the several
Underwriters listed
on Schedule I
By:
Kingswood Capital Markets, division of
Benchmark
Investments, Inc.
By:
Name: Xxx
Xxxxxxxxxx
Title:
Supervisory Principal
Address
for Notice:
00
Xxxxxxx Xxxxx
Xxx
Xxxx, XX 00000
Attention: Xxxxx X.
Xxxxx
Email:
xxxxxx@xxxxxxxxxxx.xxx
Copy
to:
Ellenoff Xxxxxxxx
& Schole LLP
0000
Xxxxxx xx xxx Xxxxxxxx
Xxx
Xxxx, XX 00000
Telephone: (000)
000-0000
Attention: Xxxxx X.
Xxxxxxxx
40
SCHEDULE
I
SCHEDULE OF UNDERWRITERS
Underwriters
|
Closing
Shares
|
Closing
Purchase Price
|
Kingswood Capital
Markets
|
3,223,500
|
$7,575,225
|
WestPark Capital,
Inc.
|
6,500
|
$15,275
|
Total
|
3,230,000
|
$7,590,500
|
41